Post a Comment
Market Buzz
Featured Posts
Introducing MY's First IPO Fund for Sophisticated Investors!
New Update. Discover investment communities that resonate with your ideas
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
Apps
Top Articles
1
2
Koon Yew Yin's Blog
CPO price is rising rapidly as shown by chart below - Koon Yew Yin
3
5
save malaysia!
Visa-free travel to China extended for Malaysians to 30 days
6
7
8
BFM Podcast
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
MQ Trading Signals
Stock
Time
Signal
Duration
No trading signals available.
Stock
Time
Signal
Duration
No trading signals available.
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
probability
14,496 posts
Posted by probability > 2021-05-13 16:23 | Report Abuse
China expected its Sinopharm vaccines to be the lynchpin of the country’s vaccine diplomacy programme – an easily transported dose that would protect not just Chinese citizens but also much of the developing world. In a bid to win goodwill, China has donated 13.3 million Sinopharm doses to other countries, according to Bridge Beijing, a consultancy that tracks China’s impact on global health.
Instead, the company, which has made two varieties of coronavirus vaccines, is facing mounting questions about the inoculations. First, there was the lack of transparency with its late-stage trial data. Now, Seychelles, the world’s most vaccinated nation, has had a surge in cases despite much of its population being inoculated with Sinopharm.
For the 56 countries counting on the Sinopharm shot to help them halt the pandemic, the news is a setback. For months, public health experts had focused on trying to close the access gap between rich and poorer nations. Now, scientists are warning that developing nations that choose to use the Chinese vaccines, with their relatively weaker efficacy rates, could end up lagging behind countries that choose vaccines made by Pfizer-BioNTech and Moderna. That gap could allow the pandemic to continue in countries that have fewer resources to fight it.
Economic benefit
...............
“You really need to use high-efficacy vaccines to get that economic benefit because otherwise they’re going to be living with the disease long-term,” said Raina MacIntyre, who heads the biosecurity programme at the Kirby Institute of the University of New South Wales in Sydney. “The choice of vaccine matters.”